What Is Immunotherapy for Cancer

1. Understanding Immunotherapy: An Overview

Immunotherapy represents a fundamental shift in cancer treatment, moving beyond directly targeting cancer cells to instead stimulating your body’s own immune system to identify and eliminate malignant growths. This approach leverages the intricate defense mechanisms that naturally exist within your body, retraining them to recognize and attack cells that have become cancerous. Unlike traditional therapies such as chemotherapy, which often have widespread effects on both healthy and cancerous cells, immunotherapy aims for a more precise and sustained response by mobilizing your internal defenses.

The core principle behind immunotherapy is the observation that your immune system possesses the capacity to distinguish between healthy cells and those that are abnormal or diseased. However, cancer cells often develop sophisticated mechanisms to evade this detection, essentially “hiding” from immune surveillance. Immunotherapy strategies are designed to counteract these evasive tactics, either by boosting the overall activity of immune cells or by specifically removing the “brakes” that prevent immune cells from attacking cancer. This can lead to a more targeted and potentially less toxic form of treatment for various cancer types.

1.1 The Immune System’s Role in Cancer

Your immune system is a complex network of cells, tissues, and organs that work together to protect your body from infections and other diseases. It is constantly surveying your body for foreign invaders and abnormal cells. When it encounters something it doesn’t recognize as “self,” it mounts a coordinated attack.

Specifically, your immune system contains specialized cells, such as T-cells, B-cells, and natural killer (NK) cells, each with distinct roles in identifying and eliminating threats. T-cells, for instance, are critical for recognizing and directly killing infected or cancerous cells. B-cells produce antibodies that can target specific antigens, while NK cells provide a rapid, non-specific response against abnormal cells. In the context of cancer, these immune cells have the potential to identify cancerous cells based on unique proteins (antigens) they express.

However, cancer cells are not static targets; they evolve and adapt to evade immune detection. They can, for example, express molecules that act as “checkpoints” to turn off immune cell activity, or they can create a microenvironment that suppresses immune responses. Understanding these evasion mechanisms is crucial for developing effective immunotherapy strategies.

1.2 Evolution of Cancer Treatment Paradigms

Historically, cancer treatment primarily relied on surgery to remove tumors, radiation therapy to destroy cancer cells with high-energy beams, and chemotherapy to kill rapidly dividing cells throughout the body. While these methods have significantly improved patient outcomes, they often come with significant side effects due to their lack of specificity.

The advent of targeted therapies marked a significant progression, focusing on specific molecular pathways that are critical for cancer cell growth and survival. These therapies, while more precise than chemotherapy, still directly target the cancer cell itself. Immunotherapy represents the next major paradigm shift, focusing on the host’s immune system rather than the tumor directly. This shift acknowledges the profound interaction between cancer and the immune system and harnesses the body’s own inherent ability to fight disease. The development of immunotherapy has opened new avenues for treating cancers that were previously considered difficult to manage, offering hope for more durable and less toxic responses.

Immunotherapy for cancer has gained significant attention in recent years as a promising treatment option that harnesses the body’s immune system to fight cancer cells. For those looking to deepen their understanding of this innovative approach, a related article titled “Understanding the Basics of Immunotherapy” provides valuable insights into how immunotherapy works, its various types, and its potential benefits and challenges. You can read more about it by visiting this link: Understanding the Basics of Immunotherapy.

2. Core Mechanisms of Immunotherapy

Immunotherapy approaches function through several distinct mechanisms, all aimed at enhancing your immune system’s ability to combat cancer. These mechanisms can broadly be categorized by how they interact with or manipulate immune cells and cancer cells. Understanding these different pathways is key to appreciating the diversity and potential of this treatment modality.

2.1 Checkpoint Inhibitors

Checkpoint inhibitors are a class of drugs that block proteins called “immune checkpoints” on the surface of immune cells or cancer cells. These checkpoints normally act as “brakes” on the immune system, preventing it from overreacting and attacking healthy tissues. However, cancer cells often exploit these checkpoints to evade immune detection and destruction. By blocking these checkpoints, checkpoint inhibitors release the brakes, allowing your immune system to recognize and attack cancer cells more effectively.

Key checkpoint proteins targeted by these inhibitors include:

PD-1 (Programmed cell death protein 1): Found on T-cells, PD-1 acts as an “off switch.” When it binds to its ligand, PD-L1 (Programmed death-ligand 1), on cancer cells or other cells in the tumor microenvironment, it deactivates the T-cell, preventing it from killing the cancer cell.
PD-L1 (Programmed death-ligand 1): Found on cancer cells and immune cells, PD-L1 binds to PD-1 on T-cells. Antibodies that block PD-L1 prevent it from binding to PD-1, thus keeping T-cells active.
CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4): Also found on T-cells, CTLA-4 acts earlier in the immune response than PD-1, primarily regulating the initial activation of T-cells. Blocking CTLA-4 can lead to a broader activation of T-cells.

By inhibiting these interactions, checkpoint inhibitors effectively re-engage your immune system’s capacity to identify and destroy cancerous cells. This mechanism has shown significant success in various cancer types, including melanoma, lung cancer, and kidney cancer, among others.

2.2 Adoptive Cell Therapy (ACT)

Adoptive cell therapy involves collecting and modifying your own immune cells, specifically T-cells, to enhance their ability to fight cancer. These modified cells are then grown in large numbers in a laboratory and reinfused into your body. This approach directly provides your immune system with a powerful army of cancer-specific fighters.

The primary forms of adoptive cell therapy include:

CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy): In CAR T-cell therapy, T-cells are extracted from your blood. In the laboratory, these T-cells are genetically engineered to produce a Chimeric Antigen Receptor (CAR) on their surface. This CAR is designed to recognize a specific protein (antigen) found on cancer cells. Once infused back into your body, these CAR T-cells can then specifically bind to and kill cancer cells expressing that antigen. This therapy has shown remarkable success in certain blood cancers, such as specific types of leukemia and lymphoma. In India, while still emerging, some major cancer centers are beginning to offer or participate in trials for CAR T-cell therapy, reflecting its global impact.
Tumor-Infiltrating Lymphocyte (TIL) therapy: TIL therapy involves isolating immune cells (lymphocytes) directly from a resected tumor. These TILs, which have already infiltrated the tumor, are often inherently equipped to recognize cancer cells. They are then expanded in large quantities in the lab and reinfused. This approach harnesses the existing anti-tumor immune response within the tumor itself.

ACT offers a highly personalized and potent form of immunotherapy, particularly for specific types of refractory cancers.

2.3 Monoclonal Antibodies (Naked Antibodies)

Monoclonal antibodies are laboratory-produced proteins that mimic the antibodies naturally made by your immune system. They are engineered to specifically bind to certain targets on cancer cells or on immune cells, either directly killing cancer cells or enhancing the immune response against them. These are often referred to as “naked” antibodies because they are not attached to drugs or radioactive particles.

Their mechanisms of action include:

Blocking “grow” signals: Some monoclonal antibodies can block growth factor receptors on cancer cells, thereby preventing signals that tell the cancer cells to grow and divide.
Triggering immune response: They can bind to cancer cells and “tag” them, making them more visible and recognizable to other immune cells, such as NK cells, which can then destroy the tagged cancer cells (a process called antibody-dependent cell-mediated cytotoxicity, or ADCC).
Blocking checkpoints: As mentioned in Section 2.1, many checkpoint inhibitors are, in fact, monoclonal antibodies designed to block PD-1, PD-L1, or CTLA-4.
Delivering toxic substances (conjugated antibodies): While primarily outside the scope of “naked” antibodies, it is important to note that monoclonal antibodies can also be conjugated (linked) to chemotherapy drugs, toxins, or radioactive particles. These “armed” antibodies deliver their toxic cargo directly to cancer cells while sparing healthy cells to a greater extent.

Monoclonal antibodies are widely used in the treatment of various cancers, including breast cancer, colorectal cancer, and lymphoma, among others. Their specificity reduces damage to healthy tissues compared to traditional chemotherapy.

2.4 Cancer Vaccines

Cancer vaccines aim to stimulate your immune system to recognize and attack cancer cells. Unlike preventive vaccines (e.g., for measles or polio) that aim to prevent infection, therapeutic cancer vaccines are designed to treat an existing cancer by boosting your immune response against it. They work by introducing cancer-specific antigens to the immune system, thereby “educating” it to identify and destroy cells expressing these antigens.

There are different types of therapeutic cancer vaccines:

Autologous vaccines: These vaccines are made using your own cancer cells or proteins derived from your tumor. The cells are often treated to make them more immunogenic before being reinjected.
Allogeneic vaccines: These vaccines use cancer cells or antigens from another individual with a similar type of cancer.
Antigen-specific vaccines: These vaccines contain specific cancer antigens (proteins or peptides) that are known to be overexpressed by cancer cells. They may also include adjuvants to further boost the immune response. For example, some vaccines target specific prostate cancer antigens.
Dendritic cell vaccines: Dendritic cells are powerful antigen-presenting cells that play a crucial role in initiating immune responses. In this approach, your own dendritic cells are extracted, exposed to cancer antigens in the lab, and then reinfused. These “primed” dendritic cells then present the cancer antigens to T-cells, training them to fight the cancer.

Cancer vaccines are still an active area of research and development, with some already approved for specific cancer types and many more undergoing clinical trials. They hold the promise of a highly specific and potentially long-lasting anti-cancer response.

2.5 Cytokines

Cytokines are small proteins that act as messengers between cells and play a critical role in regulating immune responses. Certain cytokines can directly stimulate immune cells to fight cancer. While less commonly used as standalone therapies compared to checkpoint inhibitors or CAR T-cells, they were among the first forms of immunotherapy to be utilized.

Two prominent cytokines used in cancer treatment are:

Interferons (IFNs): Interferons are naturally produced by immune cells in response to viral infections and other stimuli. They have anti-cancer effects by directly inhibiting cancer cell growth, activating immune cells (like NK cells and T-cells), and enhancing the expression of cancer antigens. Interferon-alpha, for example, has been used in the treatment of melanoma and kidney cancer.
Interleukins (ILs): Interleukins are another group of cytokines that regulate various immune cell activities. Interleukin-2 (IL-2) is known to stimulate the growth and activity of T-cells and NK cells. High-dose IL-2 has been used to treat metastatic melanoma and kidney cancer, although its use is limited by significant toxicity.

While effective in specific contexts, the systemic administration of cytokines can lead to substantial side effects due to their broad immune-activating properties. Therefore, their use requires careful patient selection and management.

3. Types of Cancers Treated with Immunotherapy

Immunotherapy has transformed the treatment landscape for a growing number of cancer types, offering new hope for patients with advanced or previously intractable diseases. The applicability of specific immunotherapy approaches varies significantly depending on the cancer type and its molecular characteristics.

3.1 Solid Tumors

Immunotherapy, particularly checkpoint inhibitors, has made substantial inroads in the treatment of various solid tumors.

Melanoma: This skin cancer was one of the first solid tumors to demonstrate dramatic and durable responses to checkpoint inhibitors (both anti-CTLA-4 and anti-PD-1/PD-L1 antibodies). Immunotherapy has become a standard of care for advanced melanoma.
Lung Cancer (Non-Small Cell Lung Cancer – NSCLC): Immunotherapy is now a frontline treatment for many patients with advanced NSCLC, especially those with tumors expressing PD-L1. It has shown superior outcomes compared to chemotherapy in certain settings.
Kidney Cancer (Renal Cell Carcinoma): Immunotherapy, both as monotherapy and in combination with other agents, has significantly improved survival rates for patients with advanced kidney cancer.
Head and Neck Squamous Cell Carcinoma (HNSCC): Checkpoint inhibitors are approved for recurrent or metastatic HNSCC, offering an important treatment option.
Bladder Cancer (Urothelial Carcinoma): Immunotherapy is used for patients with advanced bladder cancer, particularly after progression on chemotherapy or for those ineligible for platinum-based chemotherapy.
Colorectal Cancer: Immunotherapy has shown particular efficacy in a subset of colorectal cancers characterized by high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).
Hepatocellular Carcinoma (HCC): Immunotherapy combinations have emerged as a new standard for first-line treatment of advanced liver cancer.
Gastric/Gastroesophageal Junction Cancer: Immunotherapy is approved for certain patients with advanced gastric or gastroesophageal junction adenocarcinoma, often in combination with chemotherapy.

The effectiveness of immunotherapy in solid tumors can depend on factors such as the tumor’s mutational burden, PD-L1 expression, and the presence of tumor-infiltrating lymphocytes.

3.2 Hematological Malignancies (Blood Cancers)

Immunotherapy has also demonstrated profound efficacy in various blood cancers, particularly with the advent of CAR T-cell therapy.

Leukemias:
Acute Lymphoblastic Leukemia (ALL): CAR T-cell therapy has been revolutionary for pediatric and young adult patients with relapsed or refractory B-cell ALL, offering a potentially curative option.
Chronic Lymphocytic Leukemia (CLL): While not a primary indication for CAR T-cell therapy yet, checkpoint inhibitors are being explored in some contexts.
Lymphomas:
Diffuse Large B-cell Lymphoma (DLBCL): CAR T-cell therapy is approved for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy.
Follicular Lymphoma: CAR T-cell therapy is also being explored and approved for certain cases of relapsed/refractory follicular lymphoma.
Hodgkin Lymphoma: Checkpoint inhibitors are an important treatment option for patients with relapsed or refractory Hodgkin lymphoma.
Multiple Myeloma: Immunotherapy agents, including certain monoclonal antibodies targeting specific myeloma cell proteins, are part of the treatment landscape for multiple myeloma.

The success of CAR T-cell therapy in B-cell malignancies is largely due to the distinct and relatively uniform expression of specific antigens (like CD19) on these cancer cells, making them ideal targets for engineered T-cells. The landscape of immunotherapy for hematological malignancies is rapidly evolving, with new agents and approaches continuously being developed.

4. Diagnostic Considerations for Immunotherapy

Before initiating immunotherapy, a thorough diagnostic workup is essential. This workup helps determine if a patient’s cancer is likely to respond to specific immunotherapy agents and to anticipate potential side effects. These diagnostic procedures involve assessing the tumor’s characteristics, as well as the patient’s overall health and immune status.

4.1 Biomarker Testing

Biomarkers are measurable indicators of a biological state or process. In the context of immunotherapy, biomarkers are crucial for predicting treatment response and guiding therapeutic decisions.

PD-L1 Expression: One of the most widely used biomarkers is the expression level of PD-L1 on tumor cells or immune cells within the tumor microenvironment. High PD-L1 expression often correlates with a higher likelihood of response to anti-PD-1 or anti-PD-L1 checkpoint inhibitors in various solid tumors (e.g., lung cancer, bladder cancer, head and neck cancer). The test typically involves immunohistochemistry (IHC) on a tumor biopsy sample. In India, PD-L1 testing is increasingly available in major oncology centers and specialized pathology labs, though standardization across all regions remains an evolving process.
Tumor Mutational Burden (TMB): TMB refers to the total number of mutations within a tumor’s DNA. Cancers with a high TMB tend to generate more neoantigens (new proteins resulting from mutations), which the immune system can recognize as foreign. High TMB has been associated with better responses to checkpoint inhibitors in several cancer types, including melanoma and certain colorectal cancers (MSI-H/dMMR). TMB is typically assessed through next-generation sequencing (NGS) of tumor tissue.
Microsatellite Instability (MSI) / Mismatch Repair Deficiency (dMMR): MSI-H/dMMR indicates a defect in the DNA mismatch repair system, leading to an accumulation of mutations, thus resulting in a high TMB. Cancers with MSI-H/dMMR (e.g., in colorectal, endometrial, and gastric cancers) are often highly responsive to checkpoint inhibitors, regardless of their tumor origin, making it an important pan-cancer biomarker. MSI status is tested using PCR or IHC.
Other Potential Biomarkers: Research is ongoing to identify other predictive biomarkers, including the presence of specific immune cell infiltrates within the tumor, expression of other immune checkpoints, and gene expression signatures. The tumor microenvironment itself is a complex ecosystem, and understanding its components can provide further insights into immunotherapy responsiveness.

The selection and interpretation of these biomarkers require expertise in molecular pathology and oncology.

4.2 Imaging Studies

Imaging studies play a critical role in the initial staging of cancer, monitoring treatment response, and identifying potential immune-related adverse events (irAEs).

Computed Tomography (CT) Scans: CT scans provide detailed anatomical images of internal organs and are routinely used to assess tumor size, location, and spread (metastasis). For monitoring immunotherapy response, CT scans are typically performed periodically to evaluate changes in tumor size.
Positron Emission Tomography (PET) Scans (often PET-CT): PET scans use a radioactive tracer (usually FDG) to detect metabolically active cells, including cancer cells. PET-CT combines anatomical information from CT with metabolic information from PET, providing a comprehensive assessment. PET scans can be particularly useful in cases where traditional RECIST criteria (Response Evaluation Criteria in Solid Tumors) might not fully capture the response to immunotherapy, as tumors can sometimes initially appear larger due to immune cell infiltration before shrinking (pseudoprogression).
Magnetic Resonance Imaging (MRI): MRI provides detailed images of soft tissues and is particularly useful for assessing tumors in the brain, spine, and liver. For instance, brain MRIs are critical for monitoring brain metastases and for assessing neurological irAEs.

Radiological assessments during immunotherapy require specialized interpretation due to the unique response patterns that can occur.

4.3 Biopsy and Pathological Analysis

A tumor biopsy is fundamental for diagnosing cancer, determining its specific type and grade, and obtaining tissue for biomarker analysis.

Tissue Biopsy: A sample of tumor tissue is obtained, typically through a needle biopsy, endoscopic biopsy, or surgical excision. This tissue is then sent to a pathology laboratory for microscopic examination.
Histopathological Examination: A pathologist examines the tissue under a microscope to confirm the diagnosis of cancer, classify its type (e.g., adenocarcinoma, squamous cell carcinoma), and determine its grade (how aggressive it appears).
Immunohistochemistry (IHC): IHC is a specialized staining technique used on biopsy samples to detect specific proteins (like PD-L1) on cancer cells or immune cells. It helps identify specific markers that are relevant for guiding immunotherapy decisions.
Molecular Testing: In addition to IHC, molecular testing (e.g., NGS for TMB, PCR for MSI) may be performed on the biopsy tissue to identify specific genetic alterations or molecular signatures that predict response to immunotherapy.

The quality and adequacy of the biopsy sample are crucial for accurate diagnosis and biomarker testing, which directly impacts treatment selection.

4.4 Blood Tests

Routine blood tests are essential for monitoring your overall health, assessing organ function, and detecting potential side effects of immunotherapy.

Complete Blood Count (CBC): A CBC measures different types of blood cells (red blood cells, white blood cells, platelets). It helps monitor for anemia, infections, or effects on bone marrow function.
Liver Function Tests (LFTs): LFTs measure enzymes and proteins produced by the liver, indicating its health. Immunotherapy can sometimes cause inflammation of the liver (hepatitis), which would be reflected in abnormal LFTs.
Kidney Function Tests (KFTs): KFTs assess kidney health by measuring substances like creatinine and blood urea nitrogen. Immunotherapy can rarely lead to kidney inflammation (nephritis).
Thyroid Function Tests (TFTs): Immunotherapy, particularly checkpoint inhibitors, can cause inflammation of the thyroid gland (thyroiditis), leading to abnormal thyroid hormone levels. Regular monitoring of TFTs is important.
Electrolyte Levels: Monitoring electrolyte levels (e.g., sodium, potassium, calcium) is important for overall health and to detect imbalances that can arise from treatment-related side effects.
Inflammatory Markers: Markers like C-reactive protein (CRP) can indicate systemic inflammation, which might be relevant in identifying immune-related adverse events.

These blood tests help your medical team assess your eligibility for treatment, monitor for toxicity during therapy, and manage any adverse effects effectively.

Immunotherapy has emerged as a groundbreaking approach in the fight against cancer, harnessing the body’s own immune system to target and destroy cancer cells. For those looking to delve deeper into this innovative treatment, a related article can provide valuable insights into its various types and mechanisms. You can explore more about this fascinating topic by visiting this resource, which offers comprehensive information on how immunotherapy is reshaping cancer treatment and improving patient outcomes.

5. Potential Challenges and Considerations

Aspect	Description	Examples	Effectiveness	Common Side Effects
Definition	Treatment that uses the body’s immune system to fight cancer	Immune checkpoint inhibitors, CAR T-cell therapy, cancer vaccines	Varies by cancer type and patient; can lead to long-term remission	Fatigue, fever, inflammation, autoimmune reactions
Types	Different approaches to stimulate or restore immune function	Monoclonal antibodies, immune checkpoint inhibitors, cytokines	Checkpoint inhibitors effective in melanoma, lung cancer; CAR T in blood cancers	Skin rash, flu-like symptoms, organ inflammation
Mechanism	Enhances immune recognition and destruction of cancer cells	Blocking PD-1/PD-L1 or CTLA-4 pathways, T-cell modification	Can overcome tumor immune evasion mechanisms	Immune-related adverse events affecting various organs
Duration	Varies; some treatments are given over weeks to months	Checkpoint inhibitors: every 2-3 weeks; CAR T: single infusion	Long-lasting effects possible after treatment ends	Side effects may persist or appear after treatment
Success Rate	Depends on cancer type and stage	Melanoma: ~40-50% response; Lung cancer: ~20-30%	Improved survival in responsive patients	Not all patients respond; some develop resistance

While immunotherapy offers remarkable promise, it is not without its challenges and requires careful consideration. Understanding these aspects is crucial for both patients and healthcare providers.

5.1 Response Variability

One of the significant challenges in immunotherapy is the variability in patient response. Not all patients respond to immunotherapy, and even among responders, the duration and extent of response can differ widely.

Non-Responders: A substantial proportion of patients do not experience a clinical benefit from immunotherapy. This can be due to various factors, including the tumor’s immune evasion mechanisms, the presence of an immune-suppressive tumor microenvironment, or a lack of relevant targetable antigens. Identifying these patients beforehand is a major area of research.
Pseudoprogression: A unique phenomenon observed with immunotherapy is “pseudoprogression,” where tumors appear to grow or new lesions appear on imaging scans, mimicking disease progression. However, this is actually due to an influx of immune cells into the tumor, which can temporarily increase its size or metabolic activity. Over time, these tumors may then shrink. Differentiating pseudoprogression from true progression can be challenging and often requires continued treatment and repeat imaging.
Delayed Response: Unlike chemotherapy, where responses are often seen relatively quickly, immunotherapy responses can sometimes take longer to manifest. This necessitates a patient and persistent approach to treatment, especially in the absence of rapid tumor shrinkage.

Ongoing research is focused on identifying better predictive biomarkers and developing strategies to convert non-responders into responders.

5.2 Immune-Related Adverse Events (irAEs)

A distinct set of side effects, known as immune-related adverse events (irAEs), can occur with immunotherapy. These occur when the activated immune system, now unleashed from its “brakes,” mistakenly attacks healthy tissues and organs.

Mechanism: Since checkpoint inhibitors release the immune system’s brakes, immune cells can target healthy cells in various organs, leading to inflammation and damage. The specific organs affected can vary, and irAEs can range from mild to severe.
Common irAEs:
Skin: Rashes, itching.
Gastrointestinal: Colitis (inflammation of the colon) leading to diarrhea, abdominal pain.
Endocrine: Hypothyroidism or hyperthyroidism (thyroid dysfunction), adrenal insufficiency, hypophysitis (inflammation of the pituitary gland).
Liver: Hepatitis (inflammation of the liver).
Lungs: Pneumonitis (inflammation of the lungs) causing shortness of breath, cough.
Musculoskeletal: Arthritis, myalgia (muscle pain).
Rare but Severe irAEs: Less commonly, more severe irAEs can affect the heart (myocarditis), kidneys (nephritis), or nervous system (neuropathy, encephalitis).
Management: Management of irAEs typically involves close monitoring, corticosteroids to suppress the overactive immune response, and in some cases, other immunosuppressive agents. It is crucial to report any new symptoms to your healthcare team promptly. Healthcare providers in India are increasingly aware of and trained in managing these unique side effects.

Understanding and promptly managing irAEs is critical to safely and effectively administer immunotherapy.

5.3 Acquired Resistance

Even after an initial positive response, some cancers can eventually develop resistance to immunotherapy. This “acquired resistance” means that the tumor finds new ways to evade the activated immune system, leading to disease progression.

Mechanisms of Resistance: These mechanisms are diverse and can include:
Loss of antigen expression: Cancer cells may stop expressing the specific antigens that the immune system was trained to target.
Upregulation of other immune checkpoints: The tumor may start expressing different immune checkpoint proteins to suppress T-cell activity.
Changes in the tumor microenvironment: The tumor can secrete factors that suppress immune cells or recruit cells that protect the tumor from immune attack.
Loss of antigen presentation machinery: Cancer cells might lose the ability to present antigens effectively to T-cells.
Addressing Resistance: Research into understanding and overcoming acquired resistance is a major focus in oncology. Strategies being investigated include combination therapies (e.g., combining different immunotherapy agents, or immunotherapy with chemotherapy or radiation), sequential immunotherapy approaches, and developing new agents that target different immune evasion pathways.

The phenomenon of acquired resistance underscores the dynamic nature of cancer and the need for continuous innovation in treatment strategies.

5.4 Combination Strategies

Given the complexity of cancer and the various mechanisms of immune evasion, combining immunotherapy with other treatments, or even combining different immunotherapy agents, is a rapidly evolving area.

Immunotherapy Combinations:
Checkpoint inhibitor + Checkpoint inhibitor: Combining two different checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1) has shown enhanced efficacy in certain cancers (like melanoma and kidney cancer) compared to monotherapy, often at the cost of increased toxicity.
Checkpoint inhibitor + CAR T-cell therapy: This is an active area of research, aiming to improve CAR T-cell persistence and overcome resistance.
Immunotherapy + Chemotherapy: Chemotherapy can, in some cases, induce immunogenic cell death, releasing cancer antigens that can then be targeted by the immune system. This synergistic effect has led to the approval of immunotherapy-chemotherapy combinations in several cancer types (e.g., lung cancer, gastric cancer).
Immunotherapy + Radiation Therapy: Radiation therapy can not only directly kill cancer cells but also stimulate an anti-tumor immune response (known as the “abscopal effect,” where radiation to one tumor site leads to shrinkage of distant, un-irradiated tumors). Combining radiation with immunotherapy is a promising strategy to enhance systemic immune responses.
Immunotherapy + Targeted Therapy: Combining immunotherapy with targeted agents (e.g., BRAF/MEK inhibitors in melanoma, VEGF inhibitors in kidney cancer) can also be synergistic, often by altering the tumor microenvironment or directly killing cancer cells to enhance immune recognition.

These combination strategies aim to achieve more durable and potent anti-tumor responses by addressing multiple aspects of cancer biology and immune evasion. The selection of appropriate combinations is guided by tumor type, patient characteristics, and clinical trial evidence.

Disclaimer: This content is for educational purposes only and should not be considered medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment. The information provided does not replace the relationship between a patient and their physician.

FAQs

What is immunotherapy for cancer?

Immunotherapy is a type of cancer treatment that helps the immune system fight cancer. It works by boosting the body’s natural defenses to recognize and attack cancer cells.

How does immunotherapy differ from other cancer treatments?

Unlike traditional treatments like chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy enhances the body’s immune response to target and destroy cancer cells.

What types of cancer can be treated with immunotherapy?

Immunotherapy has been approved to treat various types of cancer, including melanoma, lung cancer, bladder cancer, and certain types of lymphoma and leukemia. Research is ongoing to expand its use to other types of cancer.

What are the common side effects of immunotherapy?

Common side effects of immunotherapy may include fatigue, skin reactions, flu-like symptoms, and autoimmune reactions. It is important to discuss potential side effects with your healthcare team before starting treatment.

Is immunotherapy effective for all cancer patients?

Immunotherapy has shown significant success in some cancer patients, but its effectiveness can vary depending on the type of cancer, the individual’s immune system, and other factors. Not all patients may respond to immunotherapy, and it is essential to consult with a healthcare provider to determine the best treatment approach.